Flash FinanceUS
Pre-market
S&P 5007,520.93-0.38% Nasdaq25,065.88-0.74% Dow 3052,231.89-0.30% Russell 20002,821.38-0.68% Nasdaq-10027,740.79-0.60% MidCap 4003,700.81-0.39% SmallCap 6001,716.22-0.36% VIX19.46-2.31% 10Y Yield4.98+2.45%
Close of Nov 10, 2026
AI brief of an SEC Form 8-K · Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma appoints Carol L. Brosgart as director, effective immediately

Neutral Impact 2 of 5 leadership Written later

Cocrystal Pharma's Board of Directors appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately. The filing states there are no related party transactions or family relationships that require disclosure, and it does not describe her background or committee roles.

Key points

  • Board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately
  • Filing states no arrangements or understandings tied to her selection and no related party transactions requiring disclosure under Item 404(a)
  • Report signed by CFO James Martin on August 18, 2026

The filing

CompanyCocrystal Pharma, Inc. (COCP)
Form8-K, current report
Filed with the SECAug 18, 2026, 4:30 PM ET
Accession number0001493152-26-039023

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.